bile duct cancer
Hutchmed Completes Enrollment in Phase II Trial of Fanregratinib in FGFR2-Altered Cholangiocarcinoma
The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.
SciClone Acquires Rights to Eisai's FGFR Inhibitor in Greater China
SciClone will develop and distribute Tasfygo in greater China, but Eisai will retain worldwide rights outside the region.
Relay Therapeutics Licensing FGFR2 Agent to Elevar Therapeutics for $75M
Selling the rights to lirafugratinib will allow Relay to focus on developing its PI3Kα agents.
FDA Approves Roche CDx Test for Use With Jazz Pharmaceuticals Drug in Biliary Tract Cancer
The approval is for a new indication for Roche's existing Pathway HER2 (4B5) test and is intended to identify patients with HER2-positive biliary tract cancer.
Jazz Pharmaceuticals Nabs FDA Accelerated Approval for Ziihera in HER2-Positive Biliary Tract Cancer
The approval is based on the objective response rate in a Phase IIb trial of previously treated, unresectable or metastatic biliary tract cancer patients.
Mar 14, 2024
Jun 3, 2023